皓元医药1月29日获融资买入6429.95万元，融资余额6.31亿元

Group 1 - On January 29, Haoyuan Pharmaceutical's stock fell by 5.68%, with a trading volume of 588 million yuan [1] - The financing data shows that on the same day, Haoyuan Pharmaceutical had a financing purchase amount of 64.30 million yuan and a net financing purchase of 8.90 million yuan [1] - As of January 29, the total balance of margin trading for Haoyuan Pharmaceutical was 631 million yuan, which accounts for 4.02% of its circulating market value [1] Group 2 - Haoyuan Pharmaceutical, established on September 30, 2006, is located in Shanghai and specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field [2] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42% [2] - For the period from January to September 2025, Haoyuan Pharmaceutical achieved an operating income of 2.06 billion yuan, representing a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million yuan, up by 65.09% [2] Group 3 - Since its A-share listing, Haoyuan Pharmaceutical has distributed a total of 160 million yuan in dividends, with 120 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders of Haoyuan Pharmaceutical include Hong Kong Central Clearing Limited as the second-largest shareholder, increasing its holdings by 2.35 million shares [3] - New institutional shareholders include China Europe Medical Innovation Stock A, holding 2.21 million shares, and Huatai-PineBridge Healthcare Mixed Fund, holding 1.41 million shares [3]